<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>International Journal of Preventive Medicine (Int J Prev Med)</JournalTitle><Issn>2008-7802</Issn><Volume>12</Volume><Issue>12</Issue><PubDate PubStatus="epublish"><Year>2022</Year><Month>01</Month><Day>17</Day></PubDate></Journal><title locale="en_US">The Atherogenic Index Log (Triglyceride/HDL‑Cholesterol) as a Biomarker  to Identify Type 2 Diabetes Patients with Poor Glycemic Control</title><FirstPage>2573</FirstPage><LastPage>2573</LastPage><Language>EN</Language><AuthorList><Author><affiliation locale="en_US">Department of Clinical  Biochemistry and Genetics,  Faculty of Medicine,  Mazandaran University of  Medical Sciences, Sari</affiliation></Author><Author><affiliation locale="en_US">Department of Clinical  Biochemistry and Genetics,  Faculty of Medicine,  Mazandaran University of  Medical Sciences, Sari</affiliation></Author><Author><affiliation locale="en_US">Metabolic Diseases Research  Center, Research Institute  for Prevention of NonCommunicable Diseases, Qazvin  University of Medical Sciences,  Qazvin</affiliation></Author><Author><affiliation locale="en_US">Department  of Biochemistry, Science and  Research Branch, Islamic  Azad University, Tehran</affiliation></Author><Author><affiliation locale="en_US">Molecular and Cell Biology  Research Center, Faculty of Medicine, Mazandaran  University of Medical Sciences, Sari,</affiliation></Author></AuthorList><History><PubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>17</Day></PubDate></History><abstract locale="en_US">Background: Identifying appropriate biomarkers for predicting type 2 diabetes (T2D) patients with increased HbA1c may prove helpful in preventing increased risk of cardiovascular disease (CVD). The present study was conducted to analyze the diagnostic performance of the atherogenic index log (TG/HDL‑C) in T2D patients with increased HbA1c. Methods: Patients with T2D were classified into two groups according to having an HbA1c &amp;lt;8% or ≥8%. Atherogenic index was calculated from the logarithmic transformation of TG/HDL‑C. Receiver operating characteristic curve was used to evaluate the diagnostic performance of log (TG/HDL‑C). Insulin and fasting glucose concentrations were used to determine homeostasis model assessment for insulin resistance (HOMA‑IR). Results: Compared with the patients with HbA1c &amp;lt;8%, log (TG/HDL‑C) was significantly higher in the patients with HbA1c ≥8% (p = 0.025). The atherogenic index was a biomarker for the prediction of T2D patients with HbA1c ≥8% versus patients with HbA1c &amp;lt;8%, as shown in the area under the curve (AUC = 0.61, P = 0.013). The best cut‑off point of log (TG/ HDL‑C) for the discrimination between patients with HbA1c ≥8% versus patients with HbA1c &amp;lt;8% determined to be 0.44. Atherogenic index was significantly and positively correlated with HOMA‑IR in female patients (r = 0.313, P = 0.003) and in patients with an age ≥5o (r = 0.253, P = 0.021). Conclusion: The log (TG/HDL‑C) in addition to its known association with enhanced CVD risk could be considered as a biomarker to predict T2D patients with poor glycemic control. Therefore, the increased ratio may provide a simple and useful way of identifying poor glycemic T2D patients who are possibly to be at elevated risk of CVD.</abstract><web_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/2573</web_url><pdf_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/download/2573/717718413</pdf_url></Article></Articles>
